I am not a conspiracy theorist, but there is no doubt that BIIB could have done a better job of selling Ty. Mullen has admitted that he has refrained from pushing it because of PML potential - plus Avonex is/has been their MS franchise drug. He is - as a CEO needs to be - bottom line-centric - he does not do "Patients first".
To me - that's a conflict. Ty is a more efficacious drug and with the TOUCH program, the chances of contracting PML become ever smaller as the possible causative factors become understood.
Market Data 
Markets 
AI
